METHOD OF ESTIMATION OF ACTIVE PHASE IN CHRONIC LIVER DISEASES

摘要

the invention u043eu0442u043du043eu0441u0438u0442u0441u00a0 to medicine, in particular to a hepatology. to improve the accuracy of u043eu043fu0440u0435u0434u0435u043bu0435u043du0438u00a0 u0438u0437u043eu0431u0440u0435u0442u0435u043du0438u00a0 u00a0u0432u043bu00a0u0435u0442u0441u00a0 active phase in chronic liver u0437u0430u0431u043eu043bu0435u0432u0430u043du0438u00a0u0445 and accelerating the u043eu043fu0440u0435u0434u0435u043bu0435u043du0438u00a0. in the method u043fu0440u043eu0432u043eu0434u00a0u0442 u0438u043du043au0443u0431u0430u0446u0438u044e at serum u043au0440u0432u0432u0438 and standard solutions of known concentrations of immunoglobulin e in gehle within 48 hours.further, a 6 to 7 ml of 1% solution u0442u0440u0438u0445u043bu043eu0440u0443u043au0441u0443u0441u043du043eu0439 acid for 2 - 3 minutes, u043eu043fu0440u0435u0434u0435u043bu00a0u044eu0442 level and at the level IgD IgD above 0.15 g / l u043eu043fu0440u0435u0434u0435u043bu00a0u044eu0442 availability of active x u0440u043eu043du0438u0447u0435u0441u043au043eu0433u043e u0437u0430u0431u043eu043bu0435u0432u0430u043du0438u00a0 liver way u043fu043eu0437u0432u043eu043bu00a0u0435u0442 reduce u0432u0440u0435u043cu00a0 u0438u0441u0441u043bu0435u0434u043eu0432u0430u043du0438u00a0 at 24 h and increase accuracy by persistent u043fu043eu0432u044bu0448u0435u043du0438u00a0 IgD. 1, table 2).